Drug intelligence / Profile preview

sodium p-chlorobenzoate

Development stage: Unknown
Lead developer: Meditop Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

**Mycosid** is a Meditop-marketed Hungarian over-the-counter topical antifungal powder containing sodium p-chlorobenzoate at 40 mg/g. It is indicated for prevention and treatment of superficial fungal skin infections, including dry and exudative dermatomycoses; zinc oxide and talc are listed as excipients. Product information describes local antifungal, mild astringent, and antipruritic effects, but does not specify a molecular fungal target or detailed biochemical mechanism. ([ogyei.gov.hu](https://ogyei.gov.hu/kiseroirat/bh/bh_0000013491_20100712152645.doc))

Brand names: Mycosid
Other names: nátrium paraklórbenzoátsodium 4-chlorobenzoatesodium4-chlorobenzoatesodium-4-chlorobenzoate

Beyond the preview

Go deeper on sodium p-chlorobenzoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium p-chlorobenzoate.

Explore the full profile